Health economics of insomnia treatments: The return on investment for a good night's sleep

Sleep Medicine Reviews

Volumn 30, Issue , 2016, Pages 72-82

  Wickwire, Emerson M ^a   Shaya, Fadia T ^b   Scharf, Steven M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Cognitive behavioral therapy; Cost effectiveness; Economics; Insomnia; Quality of life; Sedative hypnotic therapy; Treatment

Indexed keywords

COGNITIVE THERAPY; COMORBIDITY; CONSERVATIVE TREATMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; INSOMNIA; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEDATIVE HYPNOTIC THERAPY; SLEEP QUALITY; WORKPLACE; COST BENEFIT ANALYSIS; ECONOMICS;

COMORBIDITY; COST-BENEFIT ANALYSIS; HUMANS; QUALITY OF LIFE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84957824951     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2015.11.004     Document Type: Review

References (137)

1. American Psychiatric Association American Psychiatric Association. DSM-Task Force. Diagnostic and statistical manual of mental disorders 2013, 947.
2. Ford D.E., Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 1989, 262(11):1479-1484.
3. Ancoli-Israel S., Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I Sleep 1999, 22(Suppl. 2):S347-S353.
4. Roth T., Coulouvrat C., Hajak G., Lakoma M.D., Sampson N.A., Shahly V., et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; international statistical classification of diseases and related health problems, Tenth revision; and research diagnostic criteria/international classification of sleep disorders, second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry 2011, 69(6):592-600.
5. Stepanski E.J., Rybarczyk B. Emerging research on the treatment and etiology of secondary or comorbid insomnia. Sleep Med Rev 2006, 10(1):7-18.
6. Alattar M., Harrington J.J., Mitchell C.M., Sloane P. Sleep problems in primary care: a North Carolina family practice research network (NC-FP-RN) study. J Am Board Fam Med 2007, 20(4):365-374.
7. Kushida C.A., Nichols D.A., Simon R.D., Young T., Grauke J.H., Britzmann J.B., et al. Symptom-based prevalence of sleep disorders in an adult primary care population. Sleep Breath 2000, 4(1):9-14.
8. Taylor D.J., Mallory L.J., Lichstein K.L., Durrence H.H., Riedel B.W., Bush A.J. Comorbidity of chronic insomnia with medical problems. Sleep 2007, 30(2):213-218.
9. Sofi F., Cesari F., Casini A., Macchi C., Abbate R., Gensini G.F. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol 2014, 21(1):57-64.
10. Kyle S.D., Morgan K., Espie C.A. Insomnia and health-related quality of life. Sleep Med Rev 2010, 14(1):69-82.
11. Ishak W.W., Bagot K., Thomas S., Magakian N., Bedwani D., Larson D., et al. Quality of life in patients suffering from insomnia. Innov Clin Neurosci 2012, 9(10):13-26.
12. Neubauer D.N. New and emerging pharmacotherapeutic approaches for insomnia. Int Rev Psychiatry 2014, 26(2):214-224.
13. Neubauer D.N. Suvorexant for sleep-onset insomnia or sleep-maintenance Insomnia, or both. Curr Psychiatry 2015, 14(1):19.
14. Smith M.T., Perlis M.L., Park A., Smith M.S., Pennington J., Giles D.E., et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002, 159(1):5-11.
15. Morin C.M., Colecchi C., Stone J., Sood R., Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999, 281(11):991-999.
16. Jacobs G.D., Pace-Schott E.F., Stickgold R., Otto M.W. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004, 164(17):1888-1896.
17. Sivertsen B., Omvik S., Pallesen S., Bjorvatn B., Havik O.E., Kvale G., et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006, 295(24):2851-2858.
18. Morin C.M., Vallieres A., Guay B., Ivers H., Savard J., Merette C., et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 2009, 301(19):2005-2015.
19. NIH State of the science conference statement on manifestations and management of chronic insomnia in adults statement. J Clin Sleep Med 2005, 1(4):412-421.
20. Schutte-Rodin S., Broch L., Buysse D., Dorsey C., Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008, 4(5):487-504.
21. Morin C.M., LeBlanc M., Daley M., Gregoire J.P., Merette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006, 7(2):123-130.
22. Aikens J.E., Rouse M.E. Help-seeking for insomnia among adult patients in primary care. J Am Board Fam Pract 2005, 18(4):257-261.
23. Hatoum H.T., Kong S.X., Kania C.M., Wong J.M., Mendelson W.B. Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics 1998, 14(6):629-637.
24. National Institutes of Health National institutes of health state of the science conference statement on manifestations and management of chronic Insomnia in adults, June 13-15, 2005. Sleep 2005, 28(9):1049-1057.
25. Daley M., Morin C.M., LeBlanc M., Gregoire J.P., Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep 2009, 32(1):55-64.
26. Gooneratne N.S. Complementary and alternative medicine for sleep disturbances in older adults. Clin Geriatr Med 2008, 24(1):121-138. viii.
27. Sarris J., Byrne G.J. A systematic review of insomnia and complementary medicine. Sleep Med Rev 2011, 15(2):99-106.
28. Geiger-Brown J.M., Rogers V.E., Liu W., Ludeman E.M., Downton K.D., Diaz-Abad M. Cognitive behavioral therapy in persons with comorbid insomnia: a meta-analysis. Sleep Med Rev 2015, 23:54-67.
29. Manber R., Edinger J.D., Gress J.L., San Pedro-Salcedo M.G., Kuo T.F., Kalista T. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008, 31(4):489-495.
30. Fava M., Asnis G.M., Shrivastava R.K., Lydiard B., Bastani B., Sheehan D.V., et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry 2011, 72(7):914-928.
31. Fava M., Asnis G.M., Shrivastava R., Lydiard B., Bastani B., Sheehan D., et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol 2009, 29(3):222-230.
32. Pollack M., Kinrys G., Krystal A., McCall W.V., Roth T., Schaefer K., et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008, 65(5):551-562.
33. Talbot L.S., Maguen S., Metzler T.J., Schmitz M., McCaslin S.E., Richards A., et al. Cognitive behavioral therapy for insomnia in posttraumatic stress disorder: a randomized controlled trial. Sleep 2014, 37(2):327-341.
34. Pollack M.H., Hoge E.A., Worthington J.J., Moshier S.J., Wechsler R.S., Brandes M., et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72(7):892-897.
35. Vitiello M.V., McCurry S.M., Shortreed S.M., Balderson B.H., Baker L.D., Keefe F.J., et al. Cognitive-behavioral treatment for comorbid insomnia and osteoarthritis pain in primary care: the lifestyles randomized controlled trial. J Am Geriatr Soc 2013, 61(6):947-956.
36. Goforth H.W., Preud'homme X.A., Krystal A.D. A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep 2014, 37(6):1053-1060.
37. Arnedt J.T., Conroy D.A., Armitage R., Brower K.J. Cognitive-behavioral therapy for insomnia in alcohol dependent patients: a randomized controlled pilot trial. Behav Res Ther 2011, 49(4):227-233.
38. Vandrey R., Smith M.T., McCann U.D., Budney A.J., Curran E.M. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend 2011, 117(1):38-44.
39. Pigeon W.R., Crabtree V.M., Scherer M.R. The future of behavioral sleep medicine. J Clin Sleep Med 2007, 3(1):73-79.
40. National Commission on Sleep Disorders Research (U.S.), United States Department of Health and Human Services Wake up America a national sleep alert : report of the National Commission on Sleep Disorders Research 1993.
41. Martin S.A., Aikens J.E., Chervin R.D. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev 2004, 8(1):63-72.
42. Leger D., Bayon V. Societal costs of insomnia. Sleep Med Rev 2010, 14(6):379-389.
43. Chilcott L.A., Shapiro C.M. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics 1996, 10(Suppl. 1):1-14.
44. Stoller M.K. Economic effects of insomnia. Clin Ther 1994, 16(5):873-897. discussion 854.
45. Walsh J.K., Engelhardt C.L. The direct economic costs of insomnia in the United States for 1995. Sleep 1999, 22(Suppl. 2):S386-S393.
46. Leger D., Levy E., Paillard M. The direct costs of insomnia in France. Sleep 1999, 22(Suppl. 2):S394-S401.
47. Kaufmann C.N., Canham S.L., Mojtabai R., Gum A.M., Dautovich N.D., Kohn R., et al. Insomnia and health services utilization in middle-aged and older adults: results from the Health and Retirement Study. J Gerontol A Biol Sci Med Sci 2013, 68(12):1512-1517.
48. Bramoweth A.D., Taylor D.J. Chronic insomnia and health care utilization in young adults. Behav Sleep Med 2012, 10(2):106-121.
49. Bolge S.C., Joish V.N., Balkrishnan R., Kannan H., Drake C.L. Burden of chronic sleep maintenance insomnia characterized by nighttime awakenings. Popul Health Manag 2010, 13(1):15-20.
50. Anderson L.H., Whitebird R.R., Schultz J., McEvoy C.E., Kreitzer M.J., Gross C.R. Healthcare utilization and costs in persons with insomnia in a managed care population. Am J Manag Care 2014, 20(5). e157-e165.
51. Ozminkowski R.J., Wang S., Walsh J.K. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007, 30(3):263-273.
52. Sivertsen B., Overland S., Neckelmann D., Glozier N., Krokstad S., Pallesen S., et al. The long-term effect of insomnia on work disability: the HUNT-historical cohort study. Am J Epidemiol 2006, 163(11):1018-1024.
53. Leger D., Guilleminault C., Bader G., Levy E., Paillard M. Medical and socio-professional impact of insomnia. Sleep 2002, 25(6):625-629.
54. Leigh J.P. Employee and job attributes as predictors of absenteeism in a national sample of workers: the importance of health and dangerous working conditions. Soc Sci Med 1991, 33(2):127-137.
55. Lavie P. Sleep habits and sleep disturbances in industrial workers in Israel: main findings and some characteristics of workers complaining of excessive daytime sleepiness. Sleep 1981, 4(2):147-158.
56. Akerstedt T., Kecklund G., Alfredsson L., Selen J. Predicting long-term sickness absence from sleep and fatigue. J Sleep Res 2007, 16(4):341-345.
57. Sivertsen B., Overland S., Bjorvatn B., Maeland J.G., Mykletun A. Does insomnia predict sick leave? the Hordaland health study. J Psychosom Res 2009, 66(1):67-74.
58. Leger D., Massuel M.A., Metlaine A. SISYPHE Study Group. Professional correlates of insomnia. Sleep 2006, 29(2):171-178.
59. Sarsour K., Kalsekar A., Swindle R., Foley K., Walsh J.K. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep 2011, 34(4):443-450.
60. Hajak G., Petukhova M., Lakoma M.D., Coulouvrat C., Roth T., Sampson N.A., et al. Days-out-of-role associated with insomnia and comorbid conditions in the America Insomnia Survey. Biol Psychiatry 2011, 70(11):1063-1073.
61. Rosekind M.R., Gregory K.B. Insomnia risks and costs: health, safety, and quality of life. Am J Manag Care 2010, 16(8):617-626.
62. Bolge S.C., Doan J.F., Kannan H., Baran R.W. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res 2009, 18(4):415-422.
63. Daley M., Morin C.M., LeBlanc M., Gregoire J.P., Savard J., Baillargeon L. Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents. Sleep Med 2009, 10(4):427-438.
64. Kessler R.C., Berglund P.A., Coulouvrat C., Hajak G., Roth T., Shahly V., et al. Insomnia and the performance of US workers: results from the America insomnia survey. Sleep 2011, 34(9):1161-1171.
65. Leger D., Bayon V., Ohayon M.M., Philip P., Ement P., Metlaine A., et al. Insomnia and accidents: cross-sectional study (EQUINOX) on sleep-related home, work and car accidents in 5293 subjects with insomnia from 10 countries. J Sleep Res 2014, 23(2):143-152.
66. Kessler R.C., Berglund P.A., Coulouvrat C., Fitzgerald T., Hajak G., Roth T., et al. Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep 2012, 35(6):825-834.
67. Shahly V., Berglund P.A., Coulouvrat C., Fitzgerald T., Hajak G., Roth T., et al. The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry 2012, 69(10):1054-1063.
68. Avidan A.Y., Fries B.E., James M.L., Szafara K.L., Wright G.T., Chervin R.D. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005, 53(6):955-962.
69. Martin J.L., Alessi C.A. Limited validity of minimum data set items on sleep and hypnotic use in predicting falls and hip fracture in nursing home residents. J Am Geriatr Soc 2006, 54(7):1150-1151. author reply 152-3.
70. Glass J., Lanctot K.L., Herrmann N., Sproule B.A., Busto U.E. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005, 331(7526):1169.
71. Panneman M.J., Goettsch W.G., Kramarz P., Herings R.M. The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a pharmo study. Drugs Aging 2003, 20(11):833-839.
72. Kyle S.D., Miller C.B., Rogers Z., Siriwardena A.N., Macmahon K.M., Espie C.A. Sleep restriction therapy for insomnia is associated with reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of insomnia disorder. Sleep 2014, 37(2):229-237.
73. Botteman M. Health economics of insomnia therapy: implications for policy. Sleep Med 2009, 10(Suppl. 1):S22-S25.
74. Asche C.V., Joish V.N., Camacho F., Drake C.L. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Curr Med Res Opin 2010, 26(8):1843-1853.
75. Pollack M., Seal B., Joish V.N., Cziraky M.J. Insomnia-related comorbidities and economic costs among a commercially insured population in the United States. Curr Med Res Opin 2009, 25(8):1901-1911.
76. Tian H., Abouzaid S., Gabriel S., Kahler K.H., Kim E. Resource utilization and costs associated with insomnia treatment in patients with major depressive disorder. Prim Care Companion CNS Disord 2012, 14(5). 10.4088/PCC.12m01374. Epub 2012 Sep. 27.
77. Guyatt G.H., Feeny D.H., Patrick D.L. Measuring health-related quality of life. Ann Intern Med 1993, 118(8):622-629.
78. Kyle S.D., Morgan K., Espie C.A. Insomnia and health-related quality of life. Sleep Med Rev 2010, 14(1):69-82.
79. Ishak W.W., Bagot K., Thomas S., Magakian N., Bedwani D., Larson D., et al. Quality of life in patients suffering from insomnia. Innov Clin Neurosci 2012, 9(10):13-26.
80. Katz D.A., McHorney C.A. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002 , 51(3):229-235.
81. Dirksen S.R., Epstein D.R. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs 2008, 61(6):664-675.
82. Lindley C., Vasa S., Sawyer W.T., Winer E.P. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998, 16(4):1380-1387.
83. Pilowsky I., Crettenden I., Townley M. Sleep disturbance in pain clinic patients. Pain 1985, 23(1):27-33.
84. Stark D., Kiely M., Smith A., Velikova G., House A., Selby P. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002, 20(14):3137-3148.
85. Caap-Ahlgren M., Dehlin O. Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr 2001, 32(1):23-33.
86. Iliescu E.A., Coo H., McMurray M.H., Meers C.L., Quinn M.M., Singer M.A., et al. Quality of sleep and health-related quality of life in haemodialysis patients. Nephrol Dial Transpl 2003, 18(1):126-132.
87. Molnar M.Z., Novak M., Szeifert L., Ambrus C., Keszei A., Koczy A., et al. Restless legs syndrome, insomnia, and quality of life after renal transplantation. J Psychosom Res 2007, 63(6):591-597.
88. Nokes K.M., Kendrew J. Correlates of sleep quality in persons with HIV disease. J Assoc Nurses AIDS Care 2001, 12(1):17-22.
89. Krystal A.D., Thakur M., Roth T. Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. Ann Clin Psychiatry 2008, 20(1):39-46.
90. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
91. Kyle S.D., Crawford M.R., Morgan K., Spiegelhalder K., Clark A.A., Espie C.A. The Glasgow Sleep Impact Index (GSII): a novel patient-centred measure for assessing sleep-related quality of life impairment in insomnia disorder. Sleep Med 2013, 14(6):493-501.
92. Leger D., Scheuermaier K., Raffray T., Metlaine A., Choudat D., Guilleminault C. HD-16: a new quality of life instrument specifically designed for insomnia. Sleep Med 2005, 6(3):191-198.
93. Rombaut N., Maillard F., Kelly F., Hindmarch I. The quality of life of insomniacs questionnaire (QOLI). Med Sci Res 1990, 18(21):845-847.
94. Hajak G., Cluydts R., Declerck A., Estivill S.E., Middleton A., Sonka K., et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002, 17(1):9-17.
95. Baca E., Estivill E., Hernandez B., Lopez J. on behalf of Castivil group. Quality of life in insomnia: influence of zolpidem. J Sleep Res 2002, 11(Suppl. 1):10.
96. Leger D., Quera-Salva M.A., Philip P. Health-related quality of life in patients with insomnia treated with zopiclone. Pharmacoeconomics 1996, 10(Suppl. 1):39-44.
97. Leger D., Janus C., Pellois A., Quera-Salva M., Dreyfus J. Sleep, morning alertness and quality of life in subjects treated with zopiclone and in good sleepers. Study comparing 167 patients and 381 good sleepers. Eur Psychiatry 1995, 10(Suppl. 3):99s-102s.
98. Goldenberg F., Hindmarch I., Joyce C.R.B., Le Gal M., Partinen M., Pilate C. Zopiclone, sleep and health-related quality of life. Hum Psychopharmacol Clin Exp 1994, 9(4):245-251.
99. Scharf M., Erman M., Rosenberg R., Seiden D., McCall W.V., Amato D., et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005, 28(6):720-727.
100. Walsh J.K., Krystal A.D., Amato D.A., Rubens R., Caron J., Wessel T.C., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30(8):959-968.
101. Morin C.M., Koetter U., Bastien C., Ware J.C., Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005, 28(11):1465-1471.
102. Omvik S., Sivertsen B., Pallesen S., Bjorvatn B., Havik O.E., Nordhus I.H. Daytime functioning in older patients suffering from chronic insomnia: treatment outcome in a randomized controlled trial comparing CBT with Zopiclone. Behav Res Ther 2008, 46(5):623-641.
103. Walsh J.K., Roth T., Randazzo A., Erman M., Jamieson A., Scharf M., et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000, 23(8):1087-1096.
104. Soeffing J.P., Lichstein K.L., Nau S.D., McCrae C.S., Wilson N.M., Aguillard R.N., et al. Psychological treatment of insomnia in hypnotic-dependant older adults. Sleep Med 2008, 9(2):165-171.
105. Van Houdenhove L., Buyse B., Gabriels L., Van den Bergh O. Treating primary insomnia: clinical effectiveness and predictors of outcomes on sleep, daytime function and health-related quality of life. J Clin Psychol Med Settings 2011, 18(3):312-321.
106. Byles J.E., Mishra G.D., Harris M.A., Nair K. The problems of sleep for older women: changes in health outcomes. Age Ageing 2003, 32(2):154-163.
107. Dixon S., Morgan K., Mathers N., Thompson J., Tomeny M. Impact of cognitive behavior therapy on health-related quality of life among adult hypnotic users with chronic insomnia. Behav Sleep Med 2006, 4(2):71-84.
108. Espie C.A., MacMahon K.M., Kelly H.L., Broomfield N.M., Douglas N.J., Engleman H.M., et al. Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep 2007, 30(5):574-584.
109. Verbeek I.H., Konings G.M., Aldenkamp A.P., Declerck A.C., Klip E.C. Cognitive behavioral treatment in clinically referred chronic insomniacs: group versus individual treatment. Behav Sleep Med 2006, 4(3):135-151.
110. Thorndike F.P., Ritterband L.M., Gonder-Frederick L.A., Lord H.R., Ingersoll K.S., Morin C.M. A randomized controlled trial of an internet intervention for adults with insomnia: effects on comorbid psychological and fatigue symptoms. J Clin Psychol 2013, 69(10):1078-1093.
111. Espie C.A., Fleming L., Cassidy J., Samuel L., Taylor L.M., White C.A., et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008, 26(28):4651-4658.
112. Savard J., Simard S., Ivers H., Morin C.M. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol 2005, 23(25):6083-6096.
113. Quesnel C., Savard J., Simard S., Ivers H., Morin C.M. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol 2003, 71(1):189-200.
114. McCall W.V., Blocker J.N., D'Agostino R., Kimball J., Boggs N., Lasater B., et al. Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med 2010, 6(4):322-329.
115. Shimodera S., Watanabe N., Furukawa T.A., Katsuki F., Fujita H., Sasaki M., et al. Change in quality of life after brief behavioral therapy for insomnia in concurrent depression: analysis of the effects of a randomized controlled trial. J Clin Sleep Med 2014, 10(4):433-439.
116. Horsman J., Furlong W., Feeny D., Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003, 1:54.
117. Welch K.C., Scharf S.M. Construct validity for the Health Utilities Index in a sleep center. Sleep Breath 2007, 11(4):295-303.
118. Leger D., Morin C.M., Uchiyama M., Hakimi Z., Cure S., Walsh J.K. Chronic insomnia, quality-of-life, and utility scores: comparison with good sleepers in a cross-sectional international survey. Sleep Med 2012, 13(1):43-51.
119. Botteman M.F., Ozminkowski R.J., Wang S., Pashos C.L., Schaefer K., Foley D.J. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007, 21(4):319-334.
120. Krystal A.D., Walsh J.K., Laska E., Caron J., Amato D.A., Wessel T.C., et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26(7):793-799.
121. Nichol M.B., Sengupta N., Globe D.R. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Mak 2001, 21(2):105-112.
122. Jhaveri M., Seal B., Pollack M., Wertz D. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin 2007, 23(6):1431-1443.
123. Snedecor S.J., Botteman M.F., Bojke C., Schaefer K., Barry N., Pickard A.S. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep 2009, 32(6):817-824.
124. Lerner D., Amick B.C., Rogers W.H., Malspeis S., Bungay K., Cynn D. The work limitations questionnaire. Med Care 2001, 39(1):72-85.
125. Morgan K., Dixon S., Mathers N., Thompson J., Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess 2004, 8(8). iii-iv, 1-68.
126. Bonin E.M., Beecham J., Swift N., Raikundalia S., Brown J.S. Psycho-educational CBT-Insomnia workshops in the community. A cost-effectiveness analysis alongside a randomised controlled trial. Behav Res Ther 2014, 55:40-47.
127. Morin C.M., Belleville G., Belanger L., Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 2011, 34(5):601-608.
128. McCrae C.S., Bramoweth A.D., Williams J., Roth A., Mosti C. Impact of brief cognitive behavioral treatment for insomnia on health care utilization and costs. J Clin Sleep Med 2014, 10(2):127-135.
129. Clark D.O., Von Korff M., Saunders K., Baluch W.M., Simon G.E. A chronic disease score with empirically derived weights. Med Care 1995, 33(8):783-795.
130. Tannenbaum C., Diaby V., Singh D., Perreault S., Luc M., Vasiliadis H.M. Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US medicare perspective. Drugs Aging 2015, 32(4):305-314.
131. Woolcott J.C., Richardson K.J., Wiens M.O., Patel B., Marin J., Khan K.M., et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009, 169(21):1952-1960.
132. Stone K.L., Ensrud K.E., Ancoli-Israel S. Sleep, insomnia and falls in elderly patients. Sleep Med 2008, 9(Suppl. 1):S18-S22.
133. American Geriatrics Society 2012 Beers criteria Update Expert Panel American Geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012, 60(4):616-631.
134. Scott G.W., Scott H.M., O'Keeffe K.M., Gander P.H. Insomnia - treatment pathways, costs and quality of life. Cost Eff Resour Alloc 2011, 9(10). 7547-9-10.
135. Snedecor S.J., Botteman M.F., Schaefer K., Sarocco P., Barry N., Pickard A.S. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. J Ment Health Policy Econ 2010, 13(1):27-35.
136. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
137. Watanabe N., Furukawa T.A., Shimodera S., Katsuki F., Fujita H., Sasaki M., et al. Cost-effectiveness of cognitive behavioral therapy for insomnia comorbid with depression: analysis of a randomized controlled trial. Psychiatry Clin Neurosci 2014, 69(6):335-343.